CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company today announced publication of an article in the journal Molecular Cell describing the mechanism of enzyme inhibition of MLN4924—a small molecule inhibitor of the NEDD8-Activating Enzyme (NAE), a key component of a protein homeostasis pathway. MLN4924 is the first small molecule inhibitor that specifically targets this class of enzyme to be studied clinically, and is currently being studied in Phase I clinical trials.
